Proper Name: talimogene laherparepvec
Manufacturer: BioVex Inc., a wholly owned subsidiary of Amgen, Inc.
- For the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.
- February 10, 2023 Approval Letter - IMLYGIC
- June 30, 2022 Approval Letter (Replacement) - IMLYGIC
- June 14, 2022 Approval Letter - IMLYGIC
- December 8, 2021 Approval Letter - IMLYGIC
- Approval History, Letters, Reviews, and Related Documents - IMLYGIC
- Supporting Documents older than three years - IMLYGIC